Company / SG&A Expense
VYNE Therapeutics Inc. SG&A Expense History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$13.2M
FY2025
5-year range
$13.2M / $89.5M
FY2021-FY2025
Trend
-1.4%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
SG&A Expense has declined for 4 consecutive years, from $90M in FY2021 to $13M in FY2025.
Based on SEC 10-K filings.
$13M in FY2025 with a 5-year CAGR of -1.2%.
Improved from $16M to $13M over the past 2 years.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- -13.4%
- 5-Year CAGR
- -1.2%
- 10-Year CAGR
- -
Key checks
Key Insights
- VYNE Therapeutics Inc.'s sg&a expense has declined for 4 consecutive years.
- 5-year CAGR of -1.2%, indicating a declining trend.
- In FY2025, sg&a expense decreased 1.4% year-over-year.
- Peak sg&a expense was recorded in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -3.19 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $13.2M | -1.4% |
| FY2024 | $13.4M | -18.4% |
| FY2023 | $16.4M | -19.3% |
| FY2022 | $20.3M | -77.3% |
| FY2021 | $89.5M | +539.0% |
| FY2020 | $14.0M | +171.1% |
| FY2019 | $5.2M | +37.8% |
| FY2018 | $3.8M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026